February 23, 2015
Calixar raises €1 Million
This new round will enable the French biotech company to license-out its isolation technologies for complex therapeutic targets and viral antigens.
Conformational antibody development
Vaccine development
Ligand high-throughput screening
Structure-based drug discovery
Immunoassays
Deorphanization projects
Identification of relevant targets
Expression of full-length membrane proteins
Functional isolation and stabilization of targets
Conformational antibody development
Vaccine development
High-throughput ligand screening
Structure-based drug discovery
Immunoassays
Deorphanization projects
Identification of relevant targets
Expression of full-length membrane proteins
Functional isolation and stabilization of targets
Secure and boost
your discovery programs.
Starting from native material or recombinant systems, we succeed with all types of membrane proteins: GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins.
